Carmel Diagnostics is an Israeli privately owned healthcare company that develops clinical applications of its proprietary Thermochemiluminescence technology platform. The technology enables assessment of oxidative stress in body fluids and prediction of clinical problems linked to levels of oxidative stress.
TCL Analyzer™, a diagnostic medical device based on TCL technology, has been constructed and validated both in laboratory and pre-clinical studies.
Carmel Diagnostics focuses its activity on two major applications: prediction of Congestive Heart Failure (CHF) condition, and selection of the most promising embryo for implantation during In-Vitro Fertilization (IVF) procedures.
Proof of concept for both applications has been demonstrated in pre-clinical studies.
Carmel Diagnostics was founded by Tzali Cnaani after a management buyout of Lumitest's intellectual and tangible assets.